Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (23250)	3/19/2007 1:48:56 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Given that Dimebon is an old-line antihistamine, it probably means that the double-blind might not hold up in practice. Nothing stopping a doctor asking "Have you experienced a dry mouth or sleepiness at all?" I checked quickly and everything published I can find on the drug is from Russian sources. Be nice to have at least one US or European confirmation - even if just preclinical. Seems like a crap-shoot to me. If these results are genuine then the stock will go up from here, but no way I can see of testing that short of a new US-based trial. Peter